Research in this laboratory is focused on signal transduction mechanisms that protect prostate cancer cells from apoptosis.

This information is necessary to design more effective therapies for advanced prostate cancer and other therapy-resistant cancers.

Recently, we have identified BAD as a convergence point of several anti-apoptotic pathways downstream from PI3K/Akt, EGFR, and GPCRs. Detailed analysis of these signaling pathways revealed a complex network of remarkable redundancy that connects signals from the tumor microenvironment with BAD phosphorylation.